HD-OPM Archive

Statins: what they do and how much they help

How statins lower LDL cholesterol and what randomized trials show about heart attacks, strokes, plaque regression and long-term benefit, including the trade-offs the group discusses, such as a small rise in blood sugar.

16 min read56 group posts cited55 studies discussed5 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • In the group's summary of 25 statin outcome trials up to 2016, lowering LDL by about 75 mg/dL (1.9 mmol/L) cut heart attacks and strokes by about 40% on average versus placebo.
  • Six randomized imaging trials found total plaque volume shrank by about 5% to 17% on statins, mostly by losing soft plaque. In the 2026 FLOWPROMOTE trial, rosuvastatin plus ezetimibe took LDL to about 42.5 mg/dL and shrank total plaque 21.1% in 18 months.
  • Most of a statin's LDL lowering comes from the lowest dose: atorvastatin 10 mg lowers LDL about 37% on average, while 80 mg reaches only about 51%.
  • Over a few years the absolute benefit looks small (1-2%), but the group's admins argue it accumulates to roughly a halving of lifetime heart attack risk (from about 20% to about 10%) if LDL is lowered for decades.
  • The main metabolic trade-off is a small rise in blood sugar: in JUPITER, diabetes was diagnosed on average 5.4 weeks earlier on rosuvastatin.
In this summary
  1. How statins work
  2. What the randomized trials show
  3. Relative versus absolute benefit
  4. Safety and trade-offs
  5. Cost and the "big pharma" objection
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Statins are medicines that lower LDL cholesterol (the "bad" cholesterol carried in the blood by LDL particles) by slowing the liver's own cholesterol production. In the group's reading of the randomized trials, they reduce heart attacks, strokes and cardiovascular deaths, and the size of the benefit tracks how far LDL falls rather than which brand is used.123

The benefit is not only about the blood test. Imaging trials in which people had their coronary arteries scanned before and after treatment show that intensive statin therapy can shrink the plaque in the artery wall, mainly the soft, cholesterol-rich part that is most likely to rupture.45 Louis also stresses that statins are cheap generics,67 and that the main downside, a small rise in blood sugar, is real but modest compared with the benefit in higher-risk people.89

This article summarizes what the group's posts say about how statins work, which trials support them, how big the effect is, and where the evidence is more nuanced. It is a summary of group discussion, not medical advice; decisions about starting, stopping or changing a dose belong with your own doctor.

40%fewer heart attacks and strokes, on average, for about 75 mg/dL lower LDL across 25 statin trials1
37%average LDL drop on the lowest atorvastatin dose (10 mg); 80 mg reaches only 51%10
21.1%shrinkage of total coronary plaque in 18 months in FLOWPROMOTE (rosuvastatin plus ezetimibe)11
5.4 weekshow much earlier diabetes was diagnosed, on average, on rosuvastatin in JUPITER8

How statins work

Your liver makes cholesterol through a chain of steps, and an enzyme called HMG-CoA reductase sets the pace. Statins block that enzyme, which is why a review shared in the group describes them as inhibitors of HMG-CoA reductase acting on the mevalonate pathway.13 With less cholesterol made in the liver, the body pulls more LDL out of the blood, and LDL falls.

LDL particles carry cholesterol into artery walls, where it can build up, oxidize and trigger inflammation; this is how atherosclerotic plaque forms.14 That is the reasoning behind lowering LDL as far as is practical in people at risk.

Beyond LDL: "pleiotropic" effects

Louis Nervegna, one of the group's admins, argues that statins do more than lower LDL. These additional actions are called pleiotropic effects. His main example is the use of atorvastatin 80 mg right after a heart attack, where the benefit appears within days to weeks, which he thinks is too fast to be explained by LDL lowering alone.1516 He also notes that some researchers argue these effects partly reflect lower LDL itself, since LDL that gets into the artery wall is inflammatory.15

Other posts describe statin-related drops in Lp-PLA2, a marker of inflammation inside plaque (statin plus ezetimibe lowered it more than statin alone),17 and statin activation of an energy-sensing pathway called AMPK, which Louis argues is a mild, beneficial "mitohormesis" stress rather than harm to mitochondria.18 These are mechanistic arguments; the strongest clinical evidence in the posts is still the outcome and imaging trials below.

Which statin, and which dose?

Atorvastatin at 40-80 mg and rosuvastatin at 20-40 mg are the two high-intensity options, each typically lowering LDL by at least 50%.19 Milligram for milligram rosuvastatin is more potent, but in the head-to-head LODESTAR trial (about 4,400 adults with coronary artery disease in South Korea, 2016-2019) the two had comparable three-year outcomes for the composite of death, heart attack, stroke or revascularization. Rosuvastatin reached lower LDL but was associated with more new-onset diabetes needing medication and more cataract surgery.319

Dose matters less than many people expect. Using a slide from lipid specialist Tom Dayspring, Louis points out that atorvastatin 10 mg lowers LDL by about 37% on average, 20 mg by 43%, 40 mg by 48% and 80 mg by 51%. Each doubling adds only 6%, 5% and then 3%.102021 His practical conclusion is that a lower dose is a better strategy than quitting if side effects appear, because most of the benefit remains.10

Most of the LDL lowering comes from the first 10 mgAverage LDL reduction from untreated baseline by atorvastatin dose (Tom Dayspring slide)
10 mg37%
20 mg43%
40 mg48%
80 mg51%
Each doubling of the dose adds only 6, 5 and then 3 percentage points. Source: 1020
Show data
Value
10 mg37%
20 mg43%
40 mg48%
80 mg51%

Statins also differ in whether they enter the brain: atorvastatin is lipophilic (fat-soluble) and crosses the blood-brain barrier, whereas rosuvastatin is hydrophilic and does so poorly.22

What the randomized trials show

Heart attacks, strokes and deaths

Louis shared a chart summarizing every randomized statin outcome trial up to 2016, excluding those shorter than six months or with fewer than 50 events. It had 25 trials, 7 in primary prevention (people with no prior heart attack or stroke) and 18 in secondary prevention. On average, lowering LDL by about 75 mg/dL reduced the risk of heart attack or stroke (MACE, "major adverse cardiac events") by about 40% compared with placebo, with larger relative reductions in the primary prevention trials.12 In his example, someone at an LDL of 100 on a statin would have about 40% lower risk than someone at 175 on placebo.1

The 25 statin outcome trials Louis shared: the larger the difference in achieved LDL between the groups (horizontal axis, mmol/L), the lower the relative risk of major vascular events. Circles are primary prevention trials, squares secondary prevention.
The 25 statin outcome trials Louis shared: the larger the difference in achieved LDL between the groups (horizontal axis, mmol/L), the lower the relative risk of major vascular events. Circles are primary prevention trials, squares secondary prevention.1

For primary prevention Louis cites the JUPITER trial, in which rosuvastatin lowered heart attacks and strokes by 44% compared with placebo in just 1.9 years. He translates this into absolute terms: if your risk over two years is 3%, a halving would bring it to 1.5%.9

A pooled analysis of 27 trials from the Cholesterol Treatment Trialists' (CTT) Collaboration, covering about 174,000 participants with an average trial length of 4.9 years, found that statins work in women as well as men. Per 1 mmol/L (about 39 mg/dL) fall in LDL, major vascular events fell by 16% in women and 22% in men, and all-cause mortality by 9% and 10%, with no adverse effect on cancer incidence or non-cardiovascular mortality.23

Statins work in women as well as in menRelative reduction per 1 mmol/L (about 39 mg/dL) lower LDL, CTT meta-analysis of 27 trials, about 174,000 participants, average 4.9 years
WomenMen
Major vascular events16%22%
All-cause mortality9%10%
Reductions during the trials only; the difference between the sexes was not statistically significant for major vascular events. Source: 23
Show data
WomenMen
Major vascular events16%22%
All-cause mortality9%10%

Right after a heart attack

In PROVE IT-TIMI 22, atorvastatin 80 mg given early after an acute coronary syndrome was compared with pravastatin 40 mg. The 30-day composite of death, heart attack or rehospitalization was 3.0% versus 4.2% (hazard ratio 0.72), and in stable patients 9.6% versus 13.1%.1516 This is why Louis says patients are started on high-dose atorvastatin straight away in hospital, and advises not arguing about it while in immediate danger.15

High-dose atorvastatin right after a heart attackPROVE IT-TIMI 22: death, heart attack or rehospitalization, atorvastatin 80 mg versus pravastatin 40 mg after an acute coronary syndrome
Atorvastatin 80 mgPravastatin 40 mg
First 30 days3.0%4.2%
Stable patients9.6%13.1%
30-day hazard ratio 0.72 (95% CI 0.52–0.99). Source: 15
Show data
Atorvastatin 80 mgPravastatin 40 mg
First 30 days3.0%4.2%
Stable patients9.6%13.1%

Plaque: can statins shrink it?

Heart disease was long thought to be a one-way street. Imaging trials, which measure plaque with intravascular ultrasound (IVUS, a tiny camera inside the artery) or coronary CT angiography, suggest otherwise. Two measures appear in the posts: total atheroma volume (TAV, the total plaque volume) and percent atheroma volume (PAV, plaque as a share of the vessel).

  • Six trials with statins. Louis lists total plaque reductions relative to baseline of about 5% (COSMOS), 5.5% (SATURN), 6.5% (ASTEROID), 7.5% (IBIS-4), 8% (STABLE) and 17% (JAPAN-ACS), taken from a 2022 JACC review.42425 In that review's chart, total plaque begins to regress once LDL falls below roughly 90 mg/dL.5
  • Japan-ACS. About 300 patients with acute coronary syndrome were randomized to pitavastatin 4 mg or atorvastatin 20 mg. After 8-12 months non-culprit plaque volume changed by -16.9% and -18.1%, with LDL falling from about 130-135 to 80-85 mg/dL.2627
  • REVERSAL and ASTEROID. High-dose atorvastatin (80 mg) halted progression (PAV +0.4%) versus +2.7% on pravastatin 40 mg over 18 months, and rosuvastatin 40 mg regressed PAV by 0.98% over 24 months.28
  • SATURN. Rosuvastatin 40 mg and atorvastatin 80 mg both reduced plaque over two years in over 1,000 patients; rosuvastatin showed a somewhat greater reduction in total volume (-26.4 versus -24.4 mm3).29
  • FLOWPROMOTE (JAMA Cardiology, 2026). 104 statin-naive people with coronary disease were randomized to atorvastatin 40 mg or rosuvastatin 40 mg plus ezetimibe 10 mg, with CT angiography at baseline, 9 and 18 months. LDL averaged 69.5 versus 42.5 mg/dL; total plaque fell 13.6% versus 21.1% and non-calcified (soft) plaque 20% versus 28.2%. Lower achieved LDL was linearly associated with more regression.113031
Six statin trials: total plaque shrank 5% to 17%Change in total plaque volume from baseline in randomized imaging trials (2022 JACC review)
COSMOS−5%
SATURN−5.5%
ASTEROID−6.5%
IBIS-4−7.5%
STABLE−8%
JAPAN-ACS−17%
Different patients, doses, durations and imaging methods, so the trials are not directly comparable. Source: 424
Show data
Value
COSMOS−5%
SATURN−5.5%
ASTEROID−6.5%
IBIS-4−7.5%
STABLE−8%
JAPAN-ACS−17%
FLOWPROMOTE: lower LDL, more plaque regressionPlaque reduction over 18 months on coronary CT angiography, 104 statin-naive people with coronary disease
Atorvastatin 40 mgRosuvastatin 40 mg + ezetimibe 10 mg
Total plaque volume13.6%21.1%
Non-calcified (soft) plaque20%28.2%
Average LDL reached 69.5 versus 42.5 mg/dL. Source: 1130
Show data
Atorvastatin 40 mgRosuvastatin 40 mg + ezetimibe 10 mg
Total plaque volume13.6%21.1%
Non-calcified (soft) plaque20%28.2%

A 2021 meta-analysis of 31 IVUS studies (4,997 patients) found that lipid-lowering therapy significantly reduced plaque volume, with maximal regression at an LDL below 80 mg/dL.29 Gokhan Can's own review ranks statins, PCSK9 inhibitors and ezetimibe as the interventions with the strongest evidence for regressing or stabilizing plaque.32

Does shrinking plaque lower risk? A 2023 meta-analysis of 23 studies (7,407 patients) found each 1-percentage-point fall in PAV associated with about 19% lower odds of major cardiovascular events, but the authors of that summary stress this is an association, not proof.11 Another post puts the figure at about 20% per 1% PAV reduction.29

A puzzle: soft plaque shrinks, calcium does not

Reductions in total plaque come from losing the lipid-rich soft plaque; calcified plaque stays the same or rises.431 Several trials found statins did not slow coronary artery calcium scores (St. Francis Heart Trial, SALTIRE, BELLES), and a long-term veterans cohort reported higher odds of severe calcification with longer statin use. A review posted by Gokhan interprets this as plaque "healing", with fatty plaque turning into stable calcified scar.33 Louis makes a similar argument: calcified plaque is relatively stable, and statins help by preventing new soft plaque, regressing it and stabilizing the rest.1 This is an interpretation rather than a trial result, so people with a rising calcium score are best off asking their doctor how to read it.

Case reports are not the typical result

Louis shared a published case in which a Japanese man's severe left anterior descending artery narrowing became mild over four years on atorvastatin 10 mg, with LDL kept at 52-79 mg/dL. He is clear that this is an outlier, not what every statin user should expect; the randomized trials above show average reductions of 5% to 17%.34

Relative versus absolute benefit

A common criticism is that statin trials show only a 1-2% absolute risk reduction. Louis's reply is that these trials last about five years, during which the absolute risk of a heart attack or stroke is only 2-5% even in higher-risk people, so no treatment could reduce it by more than a few percentage points.3536

To look further out, he shared a graph combining randomized trials, prospective cohort studies and Mendelian randomization (studies that use genes that lower LDL for life). Lowering LDL by 39 mg/dL, which a very low dose statin can achieve, corresponds to more than 20% lower heart attack risk at 5 years (trials), more than 30% at 12 years (cohorts) and more than 50% at 52 years (genetic studies).35363738 With a lifetime heart attack risk of about 1 in 5 in the United States, he reasons that lowering LDL for decades could cut it from about 20% to about 10%.3537 He adds that this will not prevent every heart attack, and that diet, lifestyle and other therapies are needed for the remainder.38

The compilation chart Louis shared (Ference, European Heart Journal 2017): the same LDL reduction is linked to a larger fall in coronary heart disease risk the longer it lasts, from randomized trials (median 5 years) to cohort studies (12 years) to Mendelian randomization studies (52 years).
The compilation chart Louis shared (Ference, European Heart Journal 2017): the same LDL reduction is linked to a larger fall in coronary heart disease risk the longer it lasts, from randomized trials (median 5 years) to cohort studies (12 years) to Mendelian randomization studies (52 years).37

Gokhan reads the same style of chart as suggesting "the longer, the lower, the better": by his estimate a 70 mg/dL drop sustained for 30 years might lower lifetime risk by about 60%. He points out that effects beyond about 80 mg/dL of lowering are unknown.39 These lifetime figures are read from charts and rely on non-randomized evidence, so they are estimates rather than trial results.

Safety and trade-offs

Blood sugar

Statins modestly raise diabetes risk. In JUPITER (rosuvastatin 20 mg versus placebo, about 17,600 people, up to five years), people on the statin were diagnosed with diabetes on average 5.4 weeks earlier, and HbA1c rose by about 0.1 percentage points at 24 months. Louis's reading is that nobody got diabetes who would not otherwise have gotten it; it simply arrived earlier.840 A pooled analysis of 13 trials (91,140 patients) found that treating 255 people for four years caused one extra case of diabetes while preventing 5.4 cardiovascular events.9

A longer review posted by Gokhan adds that the risk rises with dose, is concentrated in people who already have risk factors such as impaired fasting glucose, obesity or HbA1c above 6%, and suggests ezetimibe, PCSK9 inhibitors and pitavastatin as options that limit glycemic harm.13 Some individuals report a rise in fasting insulin on rosuvastatin, and one reported an HbA1c rise that disappeared on pitavastatin. Louis cautions that rosuvastatin has the stronger trial evidence in high-risk people, so such switches should not be taken lightly.4142

Muscle aches, memory and other complaints

Muscle pain is the best-known complaint. A pooled analysis of 19 blinded trials (123,940 participants) found muscle pain or weakness in 27.1% on a statin versus 26.6% on placebo over about four years, with roughly 1 in 15 muscle complaints in the first year attributable to the statin.12 The SAMSON trial of people who had quit statins for side effects found symptoms almost as bad on placebo as on the statin, which Louis summarizes as mostly a nocebo effect (symptoms driven by expectation).912 The aches themselves are real, and some people do have genuine statin intolerance.

The CTT review also found no meaningful excess of memory loss or dementia, depression, sleep disturbance, erectile dysfunction, weight gain or fatigue, with a small (about 0.1%) increase in liver blood-test abnormalities but no increase in liver disease.43 Two randomized trials in people who already had Alzheimer's disease (simvastatin, 406 participants; atorvastatin in the LEADe trial, 640 participants) showed statins neither helped nor harmed progression.44 Whether statins can prevent dementia is being tested in two large trials: PREVENTABLE (about 20,000 adults aged 75 and over, atorvastatin 40 mg, still recruiting when posted) and STAREE (about 10,000 adults aged 70 and over); as of the group's May 2026 posts STAREE was complete, with results expected in the second half of 2026.4546 Louis infers from the fact that STAREE was neither stopped early for harm nor for benefit that the result is likely somewhere in between.47

Other points

  • Kidneys. In the PLANET trials, rosuvastatin 40 mg was linked to lower eGFR and renal adverse events in people with proteinuria, while atorvastatin 80 mg reduced proteinuria; a post hoc analysis of six trials (30,621 patients) found atorvastatin improved kidney function in a dose-dependent way.4849 A later edit clarifies that atorvastatin improved proteinuria but had no effect on eGFR.50
  • Cancer. Meta-analyses of randomized trials found no increase or decrease in cancer risk, for example an odds ratio of 0.99 for incidence in 35 trials.51 Observational data link statin use after high-risk prostate cancer diagnosis to 42% lower prostate cancer death, but that kind of data cannot prove cause and effect.5152
  • Rare case reports. One case report described fully reversible hearing loss on atorvastatin 40 mg that did not recur on rosuvastatin.53
  • Lp(a). One theory in the group is that atorvastatin's antioxidant action may blunt the harm of oxidized phospholipids on Lp(a) particles, offered as a possible reason the Lp(a) HORIZON trial did not show benefit. This is speculation from laboratory data.54

Cost and the "big pharma" objection

Louis points out that statins are off-patent. He reports paying about $7.70 for three months of atorvastatin 20 mg without insurance, about $8 for six months, and about $16 a year for his own 10 mg.6755 He argues that positive statin studies therefore do not help pharmaceutical companies, who earn more from newer patented drugs.69

What this means for you

  • Louis treats statins as well supported for people at higher risk, including right after a heart attack; the sensible step is to discuss them with your own doctor rather than rely on social media claims either way.1415
  • Remember that the biggest percentage drop in LDL comes from the lowest dose. Louis suggests lowering LDL as much as possible with diet and lifestyle first and then using the lowest statin dose that gets the job done.20 The target depends on your risk: the higher the risk, the lower to consider going.10
  • If you have side effects, the group's admins suggest asking about a lower dose or a different statin instead of quitting outright.1041 Gokhan describes trying atorvastatin, rosuvastatin, then pitavastatin and ezetimibe or Repatha before finding a combination he tolerates.4156
  • If you are at risk of diabetes, ask about monitoring HbA1c and fasting glucose; the added risk is concentrated in people who already have metabolic risk factors.813
  • Think in long-term, cumulative terms. Short trials understate the lifetime effect of lowering LDL.35
  • Ezetimibe and PCSK9 inhibitors can lower LDL further when a statin alone is not enough, or is not tolerated.3032

Frequently asked questions

Do statins actually reduce heart attacks, or only cholesterol?

The group's summary of 25 statin trials found about 40% fewer heart attacks and strokes on average for a 75 mg/dL LDL reduction, and JUPITER showed a 44% lower event rate in primary prevention.19

Can statins reverse plaque?

On average, six randomized trials found total plaque volume fell by 5% to 17% from baseline, mainly through loss of soft plaque, and FLOWPROMOTE found 13.6% to 21.1% over 18 months.411 Individual responses vary widely, and calcified plaque does not shrink.3334

Is atorvastatin or rosuvastatin better?

In LODESTAR, outcomes were comparable, though rosuvastatin lowered LDL more and was linked to more new-onset diabetes.3 Louis notes that the aim is to reach the appropriate LDL, not simply to pick the "stronger" drug.19

Do statins cause diabetes?

They modestly raise blood sugar. In JUPITER the effect was an average 5.4 weeks earlier diagnosis, and the cardiovascular benefit exceeded the diabetes hazard even in people at high diabetes risk.8

Is the muscle pain real?

The symptoms are real, but in blinded trials they occurred about as often on placebo, and only about 1 in 15 muscle complaints in the first year could be attributed to the statin.12

Do I need the highest dose?

Not necessarily. Atorvastatin 10 mg gives about 37% LDL reduction on average versus about 51% at 80 mg, though people with very high risk may be advised to aim for a lower LDL target by their doctor.1020

The evidence behind this summary55 studies · 14 meta-analyses · 25 trials · 2 MR · 3 observational

The 56 group posts cited above discuss 55 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 14Randomized trials 25Mendelian randomization 2Observational studies 3Reviews & guidelines 6Animal & lab studies 2Other sources 3

Strongest evidence discussed

All 55 studies and sources
Sources from the group (56)
  1. 25 statin trials: about 40% fewer heart attacks and strokes per 75 mg/dL LDL drop Louis Nervegna · Mar 23, 2025 · Facebook
  2. All 25 statin RCTs through 2016 show benefit: about 40% less MACE per 75 mg/dL LDL drop Louis Nervegna · May 11, 2025 · Facebook
  3. LODESTAR: rosuvastatin and atorvastatin had comparable outcomes in 4,400 patients with CAD Louis Nervegna · Jul 17, 2024 · Facebook
  4. Six randomized trials show statins reduce total plaque volume 5-17% from baseline Louis Nervegna · Mar 02, 2026 · Facebook
  5. Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs Louis Nervegna · Aug 12, 2025 · Facebook
  6. Generic statins cost about $8 for six months, so big pharma gains nothing from them Louis Nervegna · Feb 24, 2025 · Facebook
  7. Generic atorvastatin costs ~$7.70 for 3 months, so statins are not a pharma profit engine Louis Nervegna · May 14, 2025 · Facebook
  8. In JUPITER, rosuvastatin brought diabetes diagnosis forward by only 5.4 weeks Louis Nervegna · Feb 13, 2024 · Facebook
  9. What cardiologists say about statins: dementia, muscle pain, diabetes, primary prevention Louis Nervegna · Jan 13, 2026 · Facebook
  10. Most of a statin's LDL lowering comes from low doses; cut the dose rather than quit Louis Nervegna · Jan 24, 2025 · Facebook
  11. FLOWPROMOTE: rosuvastatin plus ezetimibe shrank total coronary plaque 21% in 18 months Louis Nervegna · Nov 14, 2026 · Facebook
  12. Pooled blinded trials: statins cause only about 1 in 15 reported muscle aches Louis Nervegna · Oct 23, 2026 · Facebook
  13. Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist Gokhan Can · Nov 26, 2025 · Facebook
  14. FLOWPROMOTE: rosuvastatin plus ezetimibe vs atorvastatin for plaque regression Louis Nervegna · Nov 07, 2026 · Facebook
  15. PROVE IT-TIMI 22: atorvastatin 80 mg early after a heart attack cut 30-day events 28% Louis Nervegna · Jul 31, 2024 · Facebook
  16. High-dose atorvastatin after heart attack cut events ~30% in 30 days (PROVE IT-TIMI 22) Louis Nervegna · Jan 25, 2025 · Facebook
  17. Statins, especially with ezetimibe, lower Lp-PLA2, a plaque-specific inflammation marker Louis Nervegna · Jun 22, 2025 · Facebook
  18. Statins activate AMPK via mild mitochondrial stress, which Louis argues is beneficial Louis Nervegna · Nov 23, 2023 · Facebook
  19. Rosuvastatin lowers LDL slightly more than atorvastatin; LODESTAR outcomes were similar Louis Nervegna · Aug 14, 2026 · Facebook
  20. Statin dose-response: most LDL lowering comes from the lowest dose (Dayspring slide) Louis Nervegna · Jun 15, 2025 · Facebook
  21. Statin dose-response: the lowest dose gives the biggest percentage LDL drop per mg Louis Nervegna · Oct 23, 2026 · Facebook
  22. Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't Louis Nervegna · Oct 18, 2025 · Facebook
  23. Statins work as well in women as men: 27-trial CTT meta-analysis of 174,000 participants Louis Nervegna · Dec 19, 2023 · Facebook
  24. Six RCTs show statins reverse total plaque volume by 5% to 17% Louis Nervegna · Aug 25, 2026 · Facebook
  25. Statins reverse total and soft plaque once LDL is below 70 mg/dL, Cleveland Clinic says Louis Nervegna · Sep 04, 2025 · Facebook
  26. Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18% Louis Nervegna · Sep 13, 2025 · Facebook
  27. Japan-ACS: modest statin doses cut non-culprit plaque volume by about 17-18% Louis Nervegna · Sep 18, 2025 · Facebook
  28. Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS Louis Nervegna · Jan 18, 2025 · Facebook
  29. Meta-analysis: lipid-lowering therapy regresses coronary plaque (Li 2021, SATURN) Gokhan Can · Nov 25, 2023 · Facebook
  30. FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43 Louis Nervegna · Oct 31, 2026 · Facebook
  31. FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months Louis Nervegna · Oct 31, 2026 · Facebook
  32. Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence Gokhan Can · May 18, 2024 · Facebook
  33. Statins do not slow coronary calcium; severe-calcification odds hit 4.48 after 10+ years Gokhan Can · Dec 02, 2025 · Facebook
  34. Case report: 10 mg atorvastatin cleared most of a severe LAD blockage over 4 years Louis Nervegna · Oct 06, 2025 · Facebook
  35. Statin absolute risk reduction is small over years but can exceed 10% over a lifetime Louis Nervegna · Nov 10, 2025 · Facebook
  36. Statin absolute risk reduction is cumulative: 1-2% in trials, far more over a lifetime Louis Nervegna · Sep 22, 2025 · Facebook
  37. LDL down 39 mg/dL: 20%+ fewer heart attacks in RCTs, 30%+ in cohorts, 50%+ genetically Louis Nervegna · Dec 20, 2023 · Facebook
  38. A low-dose statin could roughly halve lifetime heart attack risk if taken for decades Louis Nervegna · Feb 25, 2025 · Facebook
  39. The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction Gokhan Can · Nov 20, 2023 · Facebook
  40. Probiotics might counter statin-linked blood sugar rise via gut microbiota, editorial says Louis Nervegna · Nov 09, 2024 · Facebook
  41. Admin asks cardiologist about rosuvastatin raising insulin, and pitavastatin plus PCSK9i Gokhan Can · Dec 30, 2025 · Facebook
  42. Switching from rosuvastatin to pitavastatin removed a statin-related A1C rise in one case Louis Nervegna · Jun 04, 2026 · Facebook
  43. Statins: 0.2% yearly memory complaints on statin and placebo alike in Lancet CTT analysis Louis Nervegna · Feb 06, 2026 · Facebook
  44. Two RCTs found statins neither helped nor harmed Alzheimer's disease progression Louis Nervegna · Jun 23, 2025 · Facebook
  45. PREVENTABLE: 20,000-person trial of atorvastatin 40 mg to prevent dementia over age 75 Louis Nervegna · Jun 23, 2025 · Facebook
  46. STAREE statin trial in adults over 70 is finished; results due in second half of 2026 Louis Nervegna · May 18, 2026 · Facebook
  47. STAREE statin trial in 10,000 people over 70 is complete; no major harm or big benefit Louis Nervegna · May 26, 2026 · Facebook
  48. Rosuvastatin can stress kidneys at high dose; atorvastatin appears kidney-friendly Louis Nervegna · Jul 13, 2026 · Facebook
  49. Atorvastatin improved kidney function dose-dependently across 6 RCTs with 30,621 patients Louis Nervegna · Oct 13, 2024 · Facebook
  50. PLANET trial: atorvastatin preferred over rosuvastatin in CKD (with July 2026 correction) Louis Nervegna · Dec 06, 2025 · Facebook
  51. Statin RCT meta-analyses show no increase or decrease in cancer risk Louis Nervegna · Dec 31, 2024 · Facebook
  52. Statins after high-risk prostate cancer diagnosis linked to 42% lower cancer death Louis Nervegna · Dec 05, 2024 · Facebook
  53. Case report: atorvastatin caused fully reversible hearing loss in a 45-year-old woman Louis Nervegna · Aug 27, 2026 · Facebook
  54. Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theory for HORIZON's failure Louis Nervegna · Nov 10, 2026 · Facebook
  55. Louis takes 10 mg atorvastatin on a Mediterranean diet, like Ancel Keys' long-lived group Louis Nervegna · Aug 23, 2025 · Facebook
  56. Admin's experience adding ezetimibe, pitavastatin and Repatha after statin intolerance Gokhan Can · Jan 08, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary